Stories: EBAMed closes CHF 1.2 Million seed financing to advance non-invasive therapy for heart arrhythmias
EBAMed, an European Innovation Council pilot's funded medical technology company enabling access to non-invasive treatments for heart arrhythmias, announced the successful completion of a CHF 1.2 million seed financing round. This first investment round was led by Fongit Seed Invest with the support of FONGIT, and includes several investors.
EBAMed is developing hardware and software that expand treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients. The seed financing will be used to test EBAMed‘s first integrated ultrasound-based device to monitor heart motion and command the therapy machine. These pre-clinical tests are planned for 2020 in at least one protontherapy center in Europe or the United States.
"EBAMed’s medical device provides a non-invasive method to safely perform ablation using proton beams. The latter have the physical characteristic of depositing most of their energy in the last few millimetres of their path. By adjusting the beam’s position and energy, the targeted 3D volume, in this case the heart, can be precisely covered, sparing surrounding healthy tissues." says Giovanni Leo, Chairman of the Board and medtech industry veteran.
“Today, there are major limitations in the treatment of heart arrhythmias using invasive catheters,” said Adriano Garonna, PhD, CEO of EBAMed. “By bringing the first medical product for protontherapy of heart arrhythmias to the market, we believe we can provide medical doctors with an effective and practical method to treat more patients at an earlier stage of disease, before their quality of life has dropped significantly due to their heart arrythmia.”
EBAMed is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam.
EBAMed is a recipient of VentureKick and Horizon 2020 funds - an EIC SME Instrument Phase 1 grant in 2018, and was awarded Venture 2018 Best Business Plan, Mass Challenge Switzerland 2018 Platinum Prize and selected for IMD’s 2018 start-up program.
View EBAMed's information on the EIC SME Instrument data hub.